Elsevier

Annals of Oncology

Volume 29, Supplement 9, November 2018, Pages ix49-ix50
Annals of Oncology

Abstracts
Gastrointestinal tumours, non-colorectal
155O - Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s

https://doi.org/10.1093/annonc/mdy432.007Get rights and content
Under an Elsevier user license
open archive

Cited by (0)